Grace Life-Tech Holdings Limited has announced its interim results for the six months ended June 30, 2025. The company reported a revenue increase to USD8.42 million, up from USD5.97 million in the same period the previous year. This increase was attributed to the expansion of plant stem cell sales channels and a rise in customer numbers. The company's gross profit for the period was approximately USD1.13 million, compared to USD0.98 million previously. Significantly, the company recorded a net profit of approximately USD0.2 million for the period, a notable turnaround from a loss of approximately USD9.0 million in the prior period. Earnings per share stood at 11 US cents, compared to a loss per share of 0.60 US cents in the prior period. Despite these improvements, the Board does not recommend the payment of an interim dividend for the period. The company continues to focus on its principal business activities, including research, development, and application of plant stem cell technology, providing holistic health solutions and product sales.